- The UK's Medicines and Healthcare Products Regulatory Agency has approved Akebia Therapeutics' (NASDAQ:AKBA) Vafseo (vadadustat) for symptomatic anemia associated with chronic kidney disease.
- The approval was supported by data from 7.5K patients.
- According to the company, vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.
- Vafseo was approved in the European Union in late April.
Akebia Therapeutics wins UK approval of vadadustat for CKD anemia
Recommended For You
More Trending News
About AKBA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AKBA | - | - |
Akebia Therapeutics, Inc. |